PubRank

Ruth M Ruprecht

Author PubWeight™ 78.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004 2.47
2 Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008 2.37
3 Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J Virol 2005 2.01
4 Neutralizing antibodies as a potential secondary protective mechanism during chronic SHIV infection in CD8+ T-cell-depleted macaques. AIDS 2002 1.69
5 RNA interference--a new weapon against HIV and beyond. N Engl J Med 2002 1.68
6 Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003 1.55
7 Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 2003 1.50
8 SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 2008 1.45
9 Neutralizing antibodies against HIV -- back in the major leagues? Curr Opin Immunol 2002 1.44
10 R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS One 2010 1.29
11 An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 2011 1.24
12 Generation of recombinant vaccinia viruses via green fluorescent protein selection. DNA Cell Biol 2009 1.23
13 Characterization of HIV-1 subtype C envelope glycoproteins from perinatally infected children with different courses of disease. Retrovirology 2006 1.19
14 CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids. J Exp Med 2009 1.17
15 Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure. PLoS Negl Trop Dis 2008 1.17
16 Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol 2008 1.14
17 Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res 2007 1.13
18 Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J Virol 2008 1.13
19 Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination. J Virol 2004 1.13
20 Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 2013 1.13
21 Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 2004 1.12
22 Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis 2010 1.12
23 Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV. Vaccine 2002 1.11
24 Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology 2013 1.09
25 Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. AIDS 2007 1.08
26 The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog 2013 1.07
27 Long-term productive human immunodeficiency virus infection of CD1a-sorted myeloid dendritic cells. J Virol 2005 1.06
28 Quantitation of simian cytokine and beta-chemokine mRNAs, using real-time reverse transcriptase-polymerase chain reaction: variations in expression during chronic primate lentivirus infection. AIDS Res Hum Retroviruses 2002 1.04
29 Schistosoma mansoni infection promotes SHIV clade C replication in rhesus macaques. AIDS 2005 1.02
30 Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol 2013 1.01
31 Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 2011 1.01
32 AIDS vaccine development and challenge viruses: getting real. AIDS 2006 1.00
33 Coinfection with Schistosoma mansoni reactivates viremia in rhesus macaques with chronic simian-human immunodeficiency virus clade C infection. Infect Immun 2007 0.99
34 Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS One 2012 0.99
35 Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One 2008 0.99
36 Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One 2011 0.98
37 Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques. Virology 2006 0.97
38 Live attenuated Listeria monocytogenes expressing HIV Gag: immunogenicity in rhesus monkeys. Vaccine 2007 0.97
39 Schistosoma mansoni enhances host susceptibility to mucosal but not intravenous challenge by R5 Clade C SHIV. PLoS Negl Trop Dis 2011 0.95
40 DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. Vaccine 2005 0.94
41 Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses 2003 0.93
42 Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine. J Infect Dis 2003 0.93
43 Do not underestimate the power of antibodies--lessons from adoptive transfer of antibodies against HIV. Vaccine 2002 0.93
44 Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. Mol Ther 2012 0.89
45 Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. J Med Primatol 2010 0.88
46 Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage. J Virol 2002 0.88
47 Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus. Retrovirology 2009 0.88
48 Molecular cloning and in vitro evaluation of an infectious simian-human immunodeficiency virus containing env of a primary Chinese HIV-1 subtype C isolate. J Med Primatol 2005 0.87
49 No acquisition: a new ambition for HIV vaccine development? Curr Opin Virol 2011 0.87
50 Efficiency of neutralizing antibodies targeting the CD4-binding site: influence of conformational masking by the V2 loop in R5-tropic clade C simian-human immunodeficiency virus. J Virol 2011 0.86
51 Older rhesus macaque infants are more susceptible to oral infection with simian-human immunodeficiency virus 89.6P than neonates. J Virol 2005 0.84
52 Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection. Vaccine 2010 0.83
53 A live attenuated Listeria monocytogenes vaccine vector expressing SIV Gag is safe and immunogenic in macaques and can be administered repeatedly. Vaccine 2010 0.83
54 Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology 2013 0.83
55 Overlapping synthetic peptides as vaccines. Vaccine 2006 0.83
56 Synthesis and assembly of SIVmac Gag p27 capsid protein cholera toxin B subunit fusion protein in transgenic potato. Mol Biotechnol 2004 0.82
57 A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression. AIDS 2009 0.82
58 Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV. J Immune Based Ther Vaccines 2011 0.81
59 Truncated forms of human and simian immunodeficiency virus in infected individuals and rhesus macaques are unique or rare quasispecies. Virology 2003 0.81
60 Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol 2007 0.81
61 Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine 2009 0.81
62 AIDS and optic neuritis in a rhesus monkey infected with the R5 clade C SHIV-1157ipd3N4. J Med Primatol 2010 0.81
63 Isolation of monoclonal antibodies with predetermined conformational epitope specificity. PLoS One 2012 0.81
64 Long lasting control and lack of pathogenicity of the attenuated Rev-independent SIV in rhesus macaques. AIDS Res Hum Retroviruses 2006 0.81
65 Phosphorylation of HIV Nef by cAMP-dependent protein kinase. Virology 2005 0.81
66 R5-SHIV induces multiple defects in T cell function during early infection of rhesus macaques including accumulation of T reg cells in lymph nodes. PLoS One 2011 0.80
67 Convergent evolution of SIV env after independent inoculation of rhesus macaques with infectious proviral DNA. Virology 2003 0.80
68 Dynamics of envelope evolution in clade C SHIV-infected pig-tailed macaques during disease progression analyzed by ultra-deep pyrosequencing. PLoS One 2012 0.79
69 High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS 2012 0.79
70 Rev-independent simian immunodeficiency virus strains are nonpathogenic in neonatal macaques. J Virol 2002 0.78
71 Live attenuated Rev-independent Nef¯SIV enhances acquisition of heterologous SIVsmE660 in acutely vaccinated rhesus macaques. PLoS One 2013 0.77
72 Molecularly cloned SHIV-CN97001: a replication-competent, R5 simian/human immunodeficiency virus containing env of a primary Chinese HIV-1 clade C isolate. J Med Primatol 2011 0.77
73 Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. AIDS 2017 0.76
74 Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy. J Med Virol 2005 0.76
75 Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia. Retrovirology 2013 0.76
76 Massive occlusive thrombosis of the pulmonary artery in pigtailed macaques chronically infected with R5-tropic simian-human immunodeficiency virus. J Med Primatol 2014 0.75
77 Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression. PLoS One 2013 0.75
78 Functional aspects of binding of monoclonal antibody DCN46 to DC-SIGN on dendritic cells. Immunol Lett 2002 0.75